The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review.
Adherence
Empowerment
Long-acting injectable antipsychotics
Recovery
Schizophrenia
Shared decision-making
Journal
Annals of general psychiatry
ISSN: 1744-859X
Titre abrégé: Ann Gen Psychiatry
Pays: England
ID NLM: 101236515
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
05
2020
accepted:
16
07
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
Shared decision-making (SDM) is a process in which the doctor provides clear and complete medical information to patients about their treatment, and patients provide information on his/her preferences. Patients and clinicians bring different, but equally important, knowledge to the decision-making process. Through the adoption of SDM, it should be possible to overcome the barriers that hinder the acceptance of long-acting injectable antipsychotics (LAIs) by patients, and often also by psychiatrists. The present paper is a critical appraisal of recent literature on the impact of SDM in improving adherence to pharmacological treatments and in implementing the use of LAIs in the treatment of patients with schizophrenia. SDM is recognized as a promising strategy to improve collaboration between clinicians and patients in achieving recovery. When considering drug treatments, clinicians must evaluate the patient's preferences, expectations and concerns towards the development of a personalized treatment strategy. Moreover, an active involvement in the decision process could reduce the patient's perception of being coerced into the use of LAIs. Involving patients in the choice of therapy is not sufficient to increase pharmacological adherence if, at the same time, there is no constant work of comparison and communication with the reference psychiatric team. SDM can be particularly effective for LAI prescription, since patient can have prejudices and unjustified fears related to the LAI formulation, which the doctor must resolve.
Identifiants
pubmed: 32774442
doi: 10.1186/s12991-020-00293-4
pii: 293
pmc: PMC7409631
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
43Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsNone of the authors have any competing interests in the manuscript.
Références
World Psychiatry. 2018 Jun;17(2):170-171
pubmed: 29856548
Br J Psychiatry. 2016 Dec;209(6):517-524
pubmed: 27445354
World Psychiatry. 2019 Jun;18(2):162-163
pubmed: 31059615
World Psychiatry. 2019 Jun;18(2):119-129
pubmed: 31059635
Psychiatr Serv. 2011 Oct;62(10):1218-21
pubmed: 21969650
Psychiatry Res. 2015 Jan 30;225(1-2):14-30
pubmed: 25466227
J Ment Health. 2015 Feb;24(1):15-9
pubmed: 25734210
BMC Psychiatry. 2018 Sep 12;18(1):292
pubmed: 30223804
World Psychiatry. 2019 Feb;18(1):97-98
pubmed: 30600619
Community Ment Health J. 2014 May;50(4):375-82
pubmed: 23299226
World Psychiatry. 2018 Feb;17(1):28-29
pubmed: 29352538
Health Expect. 2016 Oct;19(5):1002-14
pubmed: 26260361
BMC Psychiatry. 2014 Apr 14;14:111
pubmed: 24725910
J Med Econ. 2013;16(2):231-9
pubmed: 23163287
World Psychiatry. 2019 Jun;18(2):165-167
pubmed: 31059625
Early Interv Psychiatry. 2016 Oct;10(5):365-77
pubmed: 26403538
World Psychiatry. 2018 Feb;17(1):12-23
pubmed: 29352540
World Psychiatry. 2019 Feb;18(1):30-31
pubmed: 30600613
World Psychiatry. 2015 Oct;14(3):270-7
pubmed: 26407772
World Psychiatry. 2018 Jun;17(2):168-169
pubmed: 29856555
Neuropsychiatr Dis Treat. 2018 Jun 08;14:1463-1474
pubmed: 29922062
World Psychiatry. 2019 Feb;18(1):42-43
pubmed: 30600633
Psychiatr Serv. 2006 Nov;57(11):1636-9
pubmed: 17085613
BMC Psychiatry. 2013 Dec 20;13:340
pubmed: 24359031
Eur Arch Psychiatry Clin Neurosci. 2019 Jun 7;:
pubmed: 31175448
Int J Mol Sci. 2016 Nov 19;17(11):
pubmed: 27869767
BMC Psychiatry. 2019 Jun 17;19(1):185
pubmed: 31208376
World Psychiatry. 2018 Jun;17(2):172-173
pubmed: 29856540
World Psychiatry. 2018 Feb;17(1):30-38
pubmed: 29352529
Eur Psychiatry. 2011 Jul-Aug;26(5):297-301
pubmed: 20570493
World Psychiatry. 2019 Feb;18(1):20-28
pubmed: 30600624
BMC Psychiatry. 2013 Feb 17;13:58
pubmed: 23414331
Soc Psychiatry Psychiatr Epidemiol. 2017 Feb;52(2):175-182
pubmed: 28040825
J Clin Psychiatry. 2016;77(suppl 3):1-24
pubmed: 27732772
Psychiatr Rehabil J. 2012 Spring;35(4):305-14
pubmed: 22491370
World Psychiatry. 2019 Oct;18(3):325-336
pubmed: 31496095
Soc Psychiatry Psychiatr Epidemiol. 2015 Mar;50(3):363-70
pubmed: 25242154
Lancet Psychiatry. 2015 Nov;2(11):1036-42
pubmed: 26404415
World Psychiatry. 2017 Jun;16(2):117-118
pubmed: 28498596
Perspect Psychiatr Care. 2017 Apr;53(2):111-118
pubmed: 26601913
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD007297
pubmed: 20091628
Psychiatr Serv. 2008 Jun;59(6):603-5
pubmed: 18511580
J Clin Psychiatry. 2019 Apr 23;80(3):
pubmed: 31050233
Encephale. 2013 Dec;39 Suppl 4:189-203
pubmed: 24373464
Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56
pubmed: 15000267
Psychiatr Serv. 2018 Dec 1;69(12):1215-1221
pubmed: 30286709
BMC Psychiatry. 2013 Oct 16;13:261
pubmed: 24131801
World Psychiatry. 2018 Oct;17(3):258-275
pubmed: 30192110
Eur Psychiatry. 2016 May;35:39-46
pubmed: 27061376
World Psychiatry. 2018 Jun;17(2):149-160
pubmed: 29856543
Psychiatr Serv. 2017 Mar 1;68(3):299-302
pubmed: 27903137
Ther Adv Psychopharmacol. 2014 Oct;4(5):179-85
pubmed: 25360242
Australas Psychiatry. 2017 Dec;25(6):578-582
pubmed: 29017332
Int J Soc Psychiatry. 2017 Dec;63(8):763-772
pubmed: 29067837
J Prof Nurs. 2014 Sep-Oct;30(5):399-405
pubmed: 25223288
Early Interv Psychiatry. 2013 Aug;7(3):247-54
pubmed: 23342964
Curr Opin Psychiatry. 2018 May;31(3):246-255
pubmed: 29474266
World Psychiatry. 2018 Jun;17(2):169-170
pubmed: 29856566
BMC Psychiatry. 2017 Feb 6;17(1):52
pubmed: 28166757
World Psychiatry. 2017 Jun;16(2):146-153
pubmed: 28498575
World Psychiatry. 2013 Jun;12(2):165-70
pubmed: 23737426
Can J Psychiatry. 2017 Sep;62(9):604-616
pubmed: 28703015
CNS Neurol Disord Drug Targets. 2017;16(8):870-884
pubmed: 28782490